Drug intelligence / Profile preview

MK-767

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-767 (also known as KRP-297) is a small molecule dual agonist of the peroxisome proliferator-activated receptors alpha (PPARα) and gamma (PPARγ). It was developed through a collaboration between Kyorin Pharmaceutical, Banyu Pharmaceutical, and Merck & Co. for the treatment of type 2 diabetes and associated dyslipidemia. By targeting both PPAR isoforms, the drug aimed to improve insulin sensitivity (via PPARγ) while simultaneously addressing lipid profiles (via PPARα). However, development was discontinued in Phase III clinical trials in 2004 due to safety concerns, specifically findings of rare tumors in long-term rodent carcinogenicity studies.

Other names: Y180U02GSBY-180U02GSBY 180U02GSB934017-32-0

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on MK-767.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-767.

Explore the full profile